Galapagos is a drug discovery company with small molecule programmes in a broad range of therapeutic areas. Galapagos was established in 1998 as a joint venture between Tibotec-Virco (acquired by Johnson & Johnson in March 2002) and Crucell. The company went public in May 2005.

LocationMechelen, Belgium
Websitewww.glpg.com